Physician

Katisha T Vance, M.D.

According to 2025 Medicare claims, Katisha Vance, M.D. (NPI: 1467526442) practices medical oncology in the Birmingham, AL market, with the plurality of this provider's patient population coming from Jefferson, AL. This provider's primary affiliated billing organization is BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC (NPI: 1841216389; TIN: 522170293) and primary practice location at 35211-1323.

Vance's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 232 traditional Medicare patients, billed 132,258 HCPCS/CPT codes, and received $2,208,271 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,548 prescription claims across 435 beneficiaries totaling $7,359,961 in drug costs, led by Revlimid (Lenalidomide). 2021 DME data shows 70 claims. Open Payments data shows 63 records totaling $83,164. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,091,245 to $7,359,961. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $7,008 to $1,163.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.2M$2.4M2015 Medicare payment: $1,442,924 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $1,838,774 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $1,775,524 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $2,347,507 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $2,397,096 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $2,437,438 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $2,114,975 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $1,959,091 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $1,763,699 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $2,208,271 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015305165,761$1,442,924
2016306203,609$1,838,774
2017277170,016$1,775,524
2018301179,963$2,347,507
2019351240,202$2,397,096
2020288176,485$2,437,438
2021343185,665$2,114,975
2022249148,119$1,959,091
2023231133,755$1,763,699
2024232132,258$2,208,271

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$3.7M$7.4M2015 Drug cost: $1,091,245 (USD; Tot_Drug_Cst)2016 Drug cost: $1,506,969 (USD; Tot_Drug_Cst)2017 Drug cost: $1,600,451 (USD; Tot_Drug_Cst)2018 Drug cost: $1,922,513 (USD; Tot_Drug_Cst)2019 Drug cost: $3,815,219 (USD; Tot_Drug_Cst)2020 Drug cost: $4,615,434 (USD; Tot_Drug_Cst)2021 Drug cost: $5,544,679 (USD; Tot_Drug_Cst)2022 Drug cost: $4,475,741 (USD; Tot_Drug_Cst)2023 Drug cost: $6,126,472 (USD; Tot_Drug_Cst)2024 Drug cost: $7,359,961 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20152431,918$1,091,245
20162362,370$1,506,969
20172272,239$1,600,451
20182362,042$1,922,513
20193032,442$3,815,219
20203072,694$4,615,434
20213192,671$5,544,679
20223362,649$4,475,741
20234093,443$6,126,472
20244353,548$7,359,961

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

DME Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: DME_Suplr_Mdcr_Pymt_Amt. Source: Medicare DME, Devices & Supplies by Referring Provider.0$5.4K$11K2015 Medicare payment: $9,182 (USD; DME_Suplr_Mdcr_Pymt_Amt)2016 Medicare payment: $2,326 (USD; DME_Suplr_Mdcr_Pymt_Amt)2017 Medicare payment: $3,396 (USD; DME_Suplr_Mdcr_Pymt_Amt)2018 Medicare payment: $10,798 (USD; DME_Suplr_Mdcr_Pymt_Amt)2019 Medicare payment: $869 (USD; DME_Suplr_Mdcr_Pymt_Amt)2020 Medicare payment: $3,526 (USD; DME_Suplr_Mdcr_Pymt_Amt)2021 Medicare payment: $4,470 (USD; DME_Suplr_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClaimsPayment
2015N/R117$9,182
2016N/R46$2,326
2017N/R57$3,396
2018N/R93$10,798
2019N/R13$869
2020N/R57$3,526
2021N/R70$4,470
2022N/RN/RN/R
2023N/RN/RN/R
2024N/RN/RN/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more90160$86
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more7993$56
G2211Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's99123$12
36415Insertion of needle into vein for collection of blood sample183572$9
85025Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count203813$7

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
RevlimidLenalidomide521,449$917,854
ImbruvicaIbrutinib411,172$684,464
KisqaliRibociclib Succinate31868$572,674
VerzenioAbemaciclib30840$454,470
LenalidomideLenalidomide35980$453,069

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.53$1,057Daiichi Sankyo Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.10$82,106AstraZeneca UK Limited
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Katisha T. Vance, M.D.?

Tedicare shows public-source Medicare data for Katisha T. Vance, M.D. (NPI 1467526442), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Katisha T. Vance, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Katisha T. Vance, M.D.?

Katisha T. Vance, M.D. is linked to BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC (billing NPI 1841216389) in the available physician profile data.

Does Katisha T. Vance, M.D. have Open Payments data?

Katisha T. Vance, M.D. has 63 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.